First Manhattan Co. held its stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,872 shares of the life sciences company’s stock at the end of the second quarter. First Manhattan Co.’s holdings in Illumina were worth $324,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of ILMN. Vanguard Group Inc. boosted its stake in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares in the last quarter. Jennison Associates LLC boosted its stake in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Geode Capital Management LLC boosted its stake in Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after buying an additional 107,941 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Illumina by 3.9% in the first quarter. Legal & General Group Plc now owns 651,314 shares of the life sciences company’s stock worth $111,142,000 after buying an additional 24,613 shares in the last quarter. Institutional investors own 93.81% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at 199.23 on Thursday. The firm has a 50-day moving average price of $178.82 and a 200-day moving average price of $173.34. Illumina, Inc. has a one year low of $119.37 and a one year high of $199.95. The stock has a market cap of $29.09 billion, a price-to-earnings ratio of 39.97 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. During the same quarter in the prior year, the business earned $0.86 earnings per share. Illumina’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2798086/first-manhattan-co-has-324000-position-in-illumina-inc-nasdaqilmn.html.
A number of analysts have recently commented on ILMN shares. Deutsche Bank AG set a $175.00 target price on Illumina and gave the stock a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and lifted their target price for the stock from $170.00 to $215.00 in a research report on Monday. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price on the stock. in a research report on Wednesday, June 21st. Morgan Stanley reiterated an “underweight” rating and set a $122.00 target price (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Finally, Barclays PLC reiterated a “hold” rating and set a $150.00 target price on shares of Illumina in a research report on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $177.01.
In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $175.53, for a total value of $2,632,950.00. Following the sale, the director now owns 534,176 shares in the company, valued at $93,763,913.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the sale, the senior vice president now owns 10,791 shares in the company, valued at approximately $1,993,637.25. The disclosure for this sale can be found here. Insiders sold 134,010 shares of company stock worth $23,946,015 in the last 90 days. 1.60% of the stock is owned by company insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.